Lunai Bioworks Inc. (LNAI) intrinsic value & 10-year financials
Lunai Bioworks Inc. (LNAI) has no Graham intrinsic value right now because the formula needs positive earnings.
- Graham intrinsic value
- —
- Share price (Oct 17, 2026)
- $0.68
- Market cap
- $112.3M
- Revenue (FY2025)
- —
- ROIC (10-yr avg)
- 11.1%
- Free cash flow (FY2025)
- —
LNAI 10-year financial history
| Fiscal year | Revenue | Net income | EPS (diluted) | Free cash flow | Operating margin | ROIC |
|---|---|---|---|---|---|---|
| FY2025 | — | -$178.0M | -$1.08 | — | — | -338.7% |
| FY2024 | — | -$80.7M | -$0.84 | -$11.0M | — | -91.7% |
| FY2023 | — | -$39.7M | -$0.71 | -$11.8M | — | -72.3% |
| FY2022 | — | -$113.4M | -$2.16 | -$15.7M | — | -105.7% |
| FY2021 | — | -$26.7M | — | -$20.7M | — | -14.8% |
| FY2020 | — | -$11.4M | — | -$10.6M | — | -7.2% |
| FY2019 | — | -$18.0M | — | -$9.2M | — | -11.0% |
| FY2018 | — | -$9.2M | — | -$4.4M | — | -10.3% |
| FY2017 | — | -$2.4M | — | — | — | 462.5% |
| FY2016 | $42.8K | -$1.7M | — | — | -4959.0% | 300.1% |
Source: annual 10-K filings on SEC EDGAR. Figures in USD.
Executive summary
Lunai Bioworks Inc. revenue growth over the past decade is N/A; insufficient history prevents a reliable 10-year CAGR calculation.
Lunai Bioworks Inc. has historically struggled to out-earn its cost of capital, averaging just -30.9% ROIC.
Over the decade, Lunai Bioworks Inc. shows that the company has leveraged its balance sheet to sustain operations.
Benjamin Graham lens
Lunai Bioworks Inc. is evaluated under Benjamin Graham's defensive framework using SEC EDGAR fundamentals using an 8.5 + 2g earnings multiple and a 5.1% AAA bond-yield baseline.